

Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience

Authors

Carmine Liberatore,^{1,2} Virginia Valeria Ferretti,³ Paola Tacchetti,⁴ Concetta Conticello,⁵ Gregorio Barilà,⁶ Elisabetta Antonioli,⁷ Angelo Belotti,⁸ Anna Maria Cafro,⁹ Laura Paris,¹⁰ Velia Bongarzone,¹¹ Massimo Gentile,^{12,13} Matteo Da Vià,¹⁴ Barbara Gamberi,¹⁵ Sara Pezzatti,¹⁶ Fabrizio Ciambelli,¹⁷ Mariagrazia Garzia,¹⁸ Ombretta Annibali,¹⁹ Francesca Fazio,²⁰ Giusy Antolino,²¹ Sonia Morè,²² Nicola Sgherza,²³ Francesca Farina,²⁴ Annalisa Citro,²⁵ Paola Steffanoni,¹⁰ Vittorio Del Fabro,²⁶ Claudio Salvatore Cartia,²⁷ Francesca Fioritoni,² Katia Mancuso,^{4,28} Irene Attucci,⁷ Maria Luisa Pioltelli,⁹ Michele Puppi,⁴ Sofia Terlizzi,⁸ Chiara Lisi,²⁰ Michele Palumbo,²⁷ Massimo Offidani,²² Maria Teresa Petrucci²⁰ and Silvia Mangiacavalli²⁷

¹Department of Medicine and Aging Sciences, “G d’Annunzio” University, Chieti, Italy; ²Hematology Unit, Santo Spirito Hospital, Pescara; ³Unit of Biostatistics and Clinical Trial Center, Fondazione IRCCS Policlinico S. Matteo, Pavia; ⁴IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna; ⁵AOU Policlinico G. Rodolico-San Marco, University School of Medicine, Catania; ⁶Hematology Unit, San Bortolo Hospital, Vicenza; ⁷Department of Hematology, Careggi Hospital and University of Florence, Florence; ⁸Department of Hematology, ASST Spedali Civili di Brescia, Brescia; ⁹Department of Hematology, GOM Niguarda Hospital, Milano; ¹⁰Department of Hematology, ASST Papa Giovanni XXIII, Bergamo; ¹¹Department of Hematology, San Giovanni-Addolorata Hospital, Roma; ¹²Department of Onco-hematology, Hematology Unit, Azienda Ospedaliera Annunziata, Cosenza; ¹³Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende; ¹⁴Hematology & BMT Unit, Fondazione IRCCS Ospedale Maggiore Policlinico di Milano,

University of Milan, Milano; ¹⁵Azienda USL - IRCCS di Reggio Emilia, Reggio Emilia; ¹⁶Department of Hematology and Transplantation, ASST di Monza, S Gerardo Hospital, Monza; ¹⁷S.C. Ematologia ASST Valle Olona Ospedale di Circolo Busto Arsizio, Busto Arsizio; ¹⁸Azienda Ospedaliera San Camillo Forlanini, UOC Hematology and Stem Cell Transplant, Roma; ¹⁹Division of Hematology, Stem Cell Transplantation, Fondazione Policlinico Universitario Campus Bio Medico, Roma; ²⁰Division of Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Universitaria Policlinico Umberto I di Roma, Sapienza University of Rome, Roma; ²¹Azienda Ospedaliero Universitaria S. Andrea, Roma; ²²Clinica di Ematologia Azienda Ospedaliero Universitaria delle Marche, Ancona; ²³Hematology and Stem Cell Transplantation Unit, AOUC Policlinico di Bari, Bari; ²⁴Hematology and BMT Unit, IRCCS Ospedale San Raffaele, Milano; ²⁵UOC Ematologia, Ospedale Civile di Legnano, Legnano; ²⁶Faculty of Medicine and Surgery, “Kore” University of Enna, Enna; ²⁷Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia and ²⁸Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy

Correspondence:

C. LIBERATORE - carmine.liberatore@asl.pe.it

<https://doi.org/10.3324/haematol.2025.289143>

Received: September 15, 2025.

Accepted: March 13, 2026.

Early view: March 26, 2026.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license



Figure S1. Progression-free survival (PFS) according to depth of response at the 3-month landmark analysis.




Figure S2. Progression-free survival (PFS) stratified by time to double refractoriness.




Table S1. Univariable Cox proportional hazard models for progression-free survival.

	N (%)	Median PFS (months)	HR (95%CI)	p-value
Age at PVd initiation				
<70 years	18	9.2	-	-
≥70 years	59	9.8	0.99 (0.49-2.00)	0.979
ISS at diagnosis				
I-II	28	16.2	-	-
III	32	8.0	1.92 (1.02-3.61)	0.043
R-ISS at diagnosis				
II	22	9.2	-	-
III	17	10.3	1.22 (0.57-2.64)	0.608
Cytogenetic profile by FISH [#] , n (%)				
low risk	13	10.8	-	-
high risk	31	8.2	1.64 (0.72-3.76)	0.239
Prior lines of therapy				
1 LOT	56	9.8	-	-
≥2 LOT	21	9.4	1.00 (0.54-1.84)	0.992
Prior ASCT				
no	65	9.8	-	-
yes	12	9.4	1.04 (0.50-2.14)	0.926
Time from first line to antiCD38-len-refractory				
<12 months	25	8.2	-	-
≥12 months	51	9.4	1.13 (0.61-2.08)	0.701
Time from first line to antiCD38-len-refractory				
<18 months	37	9.8	-	-
≥18 months	39	9.2	1.06 (0.60-1.88)	0.828
Time from first line to antiCD38-len-refractory				
<24 months	48	8.6	-	-
≥24 months	28	9.4	0.83 (0.46-1.51)	0.535
Best response to PVd regimen				
<VGPR	29	8.9	-	-
≥VGPR	32	7.3	1.11 (0.59-2.10)	0.753

Abbreviations: PVd (pomalidomide, bortezomib, dexamethasone); n (number); IQR (interquartile range); FISH (fluorescence in situ hybridization); NE (not evaluable); LOT (line of therapy); ASCT (autologous stem cell transplantation); antiCD38-len-refractory (anti-CD38 monoclonal antibodies and lenalidomide refractory); ORR (overall response rate); VGPR (very good partial response); PFS (progression-free survival); CI (confidence Interval); OS (overall survival).

[#] Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, et al. International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. *Leukemia*. 2014 Feb;28(2):269-77.